U.S. Food and Drug Administration Approves Gilead’s Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for Treatment of HIV-1 Infection
Go back to U.S. Food and Drug Administration Approves Gilead’s Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for Treatment of HIV-1 Infection| Gilead Sciences (NASDAQ: GILD) | Delayed: 145.92 -0.72 (0.49%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $146.64 | 52 Week High | $108.63 | |||
| Open | $145.46 | 52 Week Low | $71.39 | |||
| Day High | $147.68 | P/E | 80.62 | |||
| Day Low | $145.00 | EPS | $1.81 | |||
| Volume | 1,477,962 | |||||
